Cancer

For more than 45 years, the Cancer Therapeutics Department of Southern Research has been recognized nationally and internationally for its expertise in anticancer drug evaluation in experimental models. Each year we evaluate hundreds of compounds as anticancer agents for a variety of clients - government, large pharmaceutical companies, biotechnology companies, universities, foundations and individuals. As a result, we have worked with virtually every mechanistic class of anticancer agents.

Our capabilities include:

• Rapid in vitro efficacy screening utilizing more than 200 human cell lines
• In vitro mechanistic studies
• In vivo efficacy studies utilizing over 100 human tumor xenograft models
• When appropriate, in vivo efficacy studies utilizing murine tumors
• Large database including the efficacy of most clinically useful agents in these models
• Automated Data Acquisition System for rapid, accurate data generation and reporting
• Flow cytometric analysis of the effects of compounds on the expression of cell surface markers and intracellular molecules
• Assessment of the immunomodulatory and immunotoxic effects of a wide variety of compounds utilizing both in vitro and in vivo studies

The Cancer Therapeutics Department at Southern Research is proud to provide grant-based research services to the National Cancer Institute. For more information about our services, please contact William R. Waud, Ph.D. at 205-581-2426 or at waud@southernresearch.org.

Request more information on Cancer Therapeutics

See our current Grants for Cancer Therapeutics